A Phase Ib Study to Assess the Safety, Tolerability and Immunologic Activity of Preoperative IRX 2 In Early Stage Breast Cancer
Latest Information Update: 23 Aug 2024
At a glance
- Drugs Cyclophosphamide (Primary) ; Indometacin (Primary) ; IRX 2 (Primary) ; Multivitamin (Primary) ; Omeprazole (Primary) ; Zinc (Primary)
- Indications Early breast cancer; Triple negative breast cancer
- Focus Adverse reactions
- 21 Aug 2024 Planned End Date changed from 1 May 2024 to 1 Dec 2024.
- 25 Jan 2024 Planned End Date changed from 1 Jan 2023 to 1 May 2024.
- 31 Jan 2022 Planned End Date changed from 31 Dec 2020 to 1 Jan 2023.